This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.bbc.co.uk/news/uk-wales-25175772

The article has changed 3 times. There is an RSS feed of changes available.

Version 1 Version 2
Sheep help to combat C. diff super bug says biotech company Sheep help to combat C. diff super bug says biotech company
(about 1 hour later)
Sheep could hold the key to an effective treatment against a drug-resistant super bug, says a Welsh biotech company.Sheep could hold the key to an effective treatment against a drug-resistant super bug, says a Welsh biotech company.
MicroPharm Limited is looking to extract antibodies from the animal to fight Clostridium difficile (C. diff) infections in humans. MicroPharm Limited is looking to extract antibodies from the animal to fight Clostridium difficile (C. Diff) infections in humans.
If successful, clinical trials could start in humans in three years. If successful, clinical trials are starting in 2015.
Last year 1,646 people in Wales and England contracted the digestive tract infection and 10% died.Last year 1,646 people in Wales and England contracted the digestive tract infection and 10% died.
MicroPharm, based in Newcastle Emlyn, Carmarthenshire, carried out the research with the help of an £800,000 grant from the UK's innovation agency, the Technology Strategy Board.MicroPharm, based in Newcastle Emlyn, Carmarthenshire, carried out the research with the help of an £800,000 grant from the UK's innovation agency, the Technology Strategy Board.
It was part of a £2m grant awarded to Public Health England based at Porton Down and the University of Leeds.
"In some respects what we're doing isn't that revolutionary; it already occurs every day in nature," said Dr Geoff Shellswell, the company's chief operating officer."In some respects what we're doing isn't that revolutionary; it already occurs every day in nature," said Dr Geoff Shellswell, the company's chief operating officer.
"Most sheep and around 5% of humans live with C. diff in their gut and never know a thing about it. "Most sheep and around 5% of humans live with C. Diff in their gut and never know a thing about it.
"But the most common time to contract a bout of C. Diff, which will cause serious problems, is when you're receiving broad spectrum antibiotics."But the most common time to contract a bout of C. Diff, which will cause serious problems, is when you're receiving broad spectrum antibiotics.
"The drugs will knock out most other bacteria - including those which help protect against C. Diff - but because C. Diff has developed drug-resistant strains, it is left behind and can run rampant with no competition.""The drugs will knock out most other bacteria - including those which help protect against C. Diff - but because C. Diff has developed drug-resistant strains, it is left behind and can run rampant with no competition."
MicroPharm has already used its expertise with antibodies to produce anti-venoms for dangerous snakes, such as the carpet viper found in Nigeria.MicroPharm has already used its expertise with antibodies to produce anti-venoms for dangerous snakes, such as the carpet viper found in Nigeria.
To treat C. diff it is hoped that the serum could be extracted from the sheep's blood via a simple transfusion. The sheep are immunised with a very small amount of the toxins the C. Diff bacteria produces.
The sheep are immunised with a dose of C. diff, in the same way as humans are vaccinated against flu.
As they respond with an immune reaction, the antibodies created can be harvested from their blood.As they respond with an immune reaction, the antibodies created can be harvested from their blood.
"The simple part is harvesting the antibodies from the blood," said Dr Shellswell. "It's just the same as taking blood for tests and causes the sheep no harm whatsoever," said Dr Shellswell.
"It's just the same as taking blood for tests and causes the sheep no harm whatsoever.
"In fact these will probably be the most pampered sheep in the world as we need them in absolutely A1 condition."In fact these will probably be the most pampered sheep in the world as we need them in absolutely A1 condition.
"The tricky bit is then removing the unwanted parts of the blood, isolating the antibodies, and concentrating them in sufficient quantities to fight a C. diff infection in a human." "The tricky bit is then removing the unwanted parts of the blood, isolating the antibodies, and concentrating them in sufficient quantities to fight a C. Diff infection in a human.
If the current research proves successful then it is hoped that the treatment could move to a phase two clinical trial with humans in the next three years. "We have shown that the antibodies are active against the bacterial toxins in laboratory tests."
If everything then goes to plan the product could be on sale within the next 10 years. If the current research proves successful then it is hoped that the treatment could move to a phase two clinical trial with humans in the next two years.
If everything then goes to plan the product could be on sale within the next five to 10 years.